Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin

Journal of Immunology

Volumn 167, Issue 12, 2001, Pages 7192-7198

  Hwang, K K ^a   Grossman, J M ^a   Visvanathan, S ^a   Chukwuocha, R U ^a   Woods V L , Jr ^a   Le, D T ^a   Hahn, B H ^a   Chen, P P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTITHROMBIN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PROTHROMBIN; THROMBIN; THROMBIN ANTIBODY; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEEDBACK SYSTEM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; SCHOOL CHILD; THROMBOSIS;

EID: 0035893021     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.12.7192     Document Type: Article

References (43)

1. Pathogenesis of systemic lupus erythematosus
2. Antiphospholipid antibodies and thrombosis
3. Pregnancy loss in the antiphospholipid syndrome
4. Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulating lupus anticoagulant
5. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
6. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies
7. Many faces of lupus anticoagulants
8. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
9. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H)
10. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
11. Anti-prothrombin antibodies and the lupus anticoagulant
12. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
13. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
14. Some anticardiolipin antibodies recognize a combination of phospholipids with thrombin-modified antithrombin, complement C4b-binding protein, and lipopolysaccharide binding protein
15. Immunology of the antiphospholipid antibody syndrome
16. From antiphospholipid syndrome to antibody-mediated thrombosis
17. 2-glycoprotein I
18. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity
19. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies
20. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants
21. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: Comparison between different assays for the detection of antiphospholipid antibodies
22. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid
23. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies
24. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity: Discrimination between functional and non-functional anti-prothrombin-antibodies
25. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus
26. Differential effects of antiβ2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C
27. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant
28. Anti-prothrombin but not "pure" anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome
29. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome
30. Regulation of blood coagulation
31. Endothelial cell function and thrombosis
32. Blood coagulation
33. An IgG anti-prothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times
34. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay
35. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite i
36. 2-glycoprotein-1 and antiprothrombin antigen-binding fragments generated by phage display
37. Characterization of IgG monoclonal anti-cardiolipin/antiβ2GPI antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies
38. Blood coagulation and fibrinolysis
39. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor ii
40. A player of many parts: The spotlight falls on thrombin's structure
41. Role of endothelial cell surface heparin-like polysaccharides
42. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: Resolution of the antithrombin conformational change contribution to heparin rate enhancement
43. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder